Vivus Jumps as FDA Allows Wider Sales of Obesity Drug

Vivus Inc. (VVUS) rose the most in three months after U.S. regulators said the drugmaker can sell its obesity pill Qsymia in more pharmacies than first allowed.

Vivus gained 3.5 percent to $11.55 at 3:23 p.m. New York time, after advancing as much as 11 percent in the biggest intraday increase since Jan. 7. The company had fallen by more than half since winning approval for the drug on July 17, as sales were slower than investors expected.

Qsymia, which the Food and Drug Administration restricted to sales through certain mail-order pharmacies, can now be offered through certified retail pharmacies as well, the Mountain View, California-based company said today in a statement. Vivus’s goal is to make Qsymia available in thousands of retailers over the next three months, President Peter Tam said in the statement.

The change “is a key accomplishment in removing a major barrier that has hindered the initial acceptance of Qsymia into everyday medical practice,” Tam said. “Retail access, along with ongoing improvements in reimbursement, will help to accelerate Qsymia awareness, trial and usage.”

Qsymia is a combination of the appetite suppressant phentermine and the antiseizure drug topiramate, both of which are available separately in generic form. Qsymia accounted for 2.5 percent of total obesity prescriptions as of April 5, compared with 87 percent for phentermine, Andrew Berens, an analyst with Bloomberg Industries, said yesterday in a report.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.